Videos

Metastatic Prostate Cancer: Case 2

June 18th 2015

Metastatic Prostate Cancer

E. David Crawford, MD: Chemotherapy Consideration

June 18th 2015

E. David Crawford, MD: Influences on Treatment Options

June 18th 2015

E. David Crawford, MD: Safety and Tolerability Issues

June 18th 2015

E. David Crawford, MD: Options to Control Recurrent Metastatic Disease

June 18th 2015

Judd W. Moul, MD, FACS: Chemotherapy Consideration

June 18th 2015

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

June 18th 2015

Metastatic Prostate Cancer: Case 1

June 18th 2015

Metastatic Prostate Cancer

Pierre Gholam, MD: Treatment Selection

June 18th 2015

Pierre Gholam, MD: Alcohol Abuse Impact on Treatment

June 18th 2015

Nicholas Nissen, MD: Treatment Selection

June 18th 2015

Nicholas Nissen, MD: Monitoring of Patient

June 18th 2015

Richard Finn, MD: Treatment Selection

June 18th 2015

Richard Finn, MD: Most Appropriate Treatment

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 3

June 18th 2015

Unresectable Hepatocellular Carcinoma

Pierre Gholam, MD: Potential for Systemic Therapy

June 18th 2015

Pierre Gholam, MD: Recommended Screening

June 18th 2015

Nicholas Nissen, MD: Potential for Systemic Therapy

June 18th 2015

Nicholas Nissen, MD: Estimate of TACE Procedures

June 18th 2015

Richard Finn, MD: Potential for Systemic Therapy

June 18th 2015

Richard Finn, MD: Significance of Baseline AFP Levels

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 2

June 18th 2015

Unresectable Hepatocellular Carcinoma

Pierre Gholam, MD: Consideration of Different Modalities

June 18th 2015

Pierre Gholam, MD: Next Steps for Jose

June 18th 2015

Nicholas Nissen, MD: Next Steps for Jose

June 18th 2015

Nicholas Nissen, MD: Consideration of Different Modalities

June 18th 2015

Richard Finn, MD: Next Steps for Jose

June 18th 2015

Richard Finn, MD: Consideration of Different Modalities

June 18th 2015

Unresectable Hepatocellular Carcinoma: case 1

June 18th 2015

Unresectable Hepatocellular Carcinoma

Denise A Yardley MD: Controlling Metastatic Disease

June 18th 2015

Videos

Metastatic Prostate Cancer: Case 2

E. David Crawford, MD: Chemotherapy Consideration

E. David Crawford, MD: Influences on Treatment Options

E. David Crawford, MD: Safety and Tolerability Issues

E. David Crawford, MD: Options to Control Recurrent Metastatic Disease

Judd W. Moul, MD, FACS: Chemotherapy Consideration

Judd W. Moul, MD, FACS: Options to Control Recurrent Metastatic Disease

Metastatic Prostate Cancer: Case 1

Pierre Gholam, MD: Treatment Selection

Pierre Gholam, MD: Alcohol Abuse Impact on Treatment

Nicholas Nissen, MD: Treatment Selection

Nicholas Nissen, MD: Monitoring of Patient

Richard Finn, MD: Treatment Selection

Richard Finn, MD: Most Appropriate Treatment

Unresectable Hepatocellular Carcinoma: case 3

Pierre Gholam, MD: Potential for Systemic Therapy

Pierre Gholam, MD: Recommended Screening

Nicholas Nissen, MD: Potential for Systemic Therapy

Nicholas Nissen, MD: Estimate of TACE Procedures

Richard Finn, MD: Potential for Systemic Therapy

Richard Finn, MD: Significance of Baseline AFP Levels

Unresectable Hepatocellular Carcinoma: case 2

Pierre Gholam, MD: Consideration of Different Modalities

Pierre Gholam, MD: Next Steps for Jose

Nicholas Nissen, MD: Next Steps for Jose

Nicholas Nissen, MD: Consideration of Different Modalities

Richard Finn, MD: Next Steps for Jose

Richard Finn, MD: Consideration of Different Modalities

Unresectable Hepatocellular Carcinoma: case 1

Denise A Yardley MD: Controlling Metastatic Disease

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma

PTCy Fails to Translate GVHD Reduction to Survival Advantage Vs ATG

FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer

Oncologists Perceive Shift Away from Surgery in Progressive Desmoid Tumors

Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer